Results 131 to 140 of about 221,455 (333)

Rituximab Treatment in a Patient with Active Graves’ Orbitopathy and Psoriasis

, 2017
Management of Graves’ orbitopathy remains an important therapeutic challenge. Current therapeutic modalities are unsatisfactory in about one third of patients.
Nur Kebapçı, Nilgün Yıldırım, Belgin Efe, Tülay Şimşek, Şimşek, Tülay, Yıldırım, Nilgün, Efe, Belgin, Kebapci, Nur   +7 more
core   +1 more source

Association of Elevated Platelets and C‐Reactive Protein With Severe Disease and Poor Survival in Systemic Sclerosis

Arthritis Care &Research, EarlyView.
Objective Elevated C‐reactive protein (CRP) levels in systemic sclerosis (SSc) have been linked with severe disease and worse survival, but the role of platelet levels remains unclear. This study examined whether elevated platelet levels, CRP levels, or both are associated with disease severity, progression, and survival in SSc.
Brian S. Lee, Shufeng Li, Srijana Davuluri, Jennifer Lee, Lorinda Chung   +4 more
wiley   +1 more source

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

New England Journal of Medicine, 2002
B. Coiffier, É. Lepage, J. Briére, R. Herbrecht, H. Tilly, R. Bouabdallah, P. Morel, E. Van Den Neste, G. Salles, P. Gaulard, F. Reyes, P. Lederlin, C. Gisselbrecht   +12 more
semanticscholar   +2 more sources

A Case of Primary Biliary Cirrhosis That Progressed Rapidly after Treatment Involving Rituximab

Case Reports in Gastroenterology, 2013
Primary biliary cirrhosis (PBC) is a progressive liver disease for which limited therapies are recommended. Rituximab, an anti-CD20 monoclonal antibody, is expected to be a useful therapeutic regimen for PBC.
Kazuto Tajiri, Koichi Tsuneyama, Takahiro Miyazono, Kengo Kawai, Masami Minemura, Toshiro Sugiyama   +5 more
doaj   +1 more source

Clinician and Patient Factors Associated With Long‐Term Glucocorticoid Use in People With Rheumatoid Arthritis Receiving Advanced Therapies

Arthritis Care &Research, EarlyView.
Objective Despite guideline recommendations, long‐term glucocorticoid (GC) use is common in rheumatoid arthritis (RA). We conducted a clinician survey nested within a large registry to identify patient and clinician factors associated with GC use. Methods Clinicians contributing patients to the CorEvitas Rheumatoid Arthritis Registry were surveyed ...
Michael D. George, George Reed, Matthew D. Kearney, Peter F. Cronholm, Kevin Kane, Jeffrey R. Curtis, Dimitrios A. Pappas, Joel M. Kremer   +7 more
wiley   +1 more source

Beyond Nature's Blueprint: Macrocyclic Peptides Containing Unnatural Amino Acids in Therapeutic Development

Angewandte Chemie, EarlyView.
Strategic incorporation of unnatural amino acids transforms macrocyclic peptides into drug‐like molecules capable of engaging challenging targets. These building blocks enhance stability, permeability, and bioavailability, accelerating the development of next‐generation peptide therapeutics.
Krishna K. Sharma, Komal Sharma, Anku Sharma, Kamya Rao, Rahul Jain, Brett VanVeller   +5 more
wiley   +2 more sources

Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma

BMC Cancer, 2017
Background The addition of rituximab (R) to CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) -like therapy has improved survival in primary mediastinal B-cell lymphoma (PMBCL) patients.
K. Lisenko, G. Dingeldein, M. Cremer, M. Kriegsmann, A. D. Ho, M. Rieger, M. Witzens-Harig   +6 more
doaj   +1 more source

Impact of Six‐Month Monitoring Compared to Three‐Month Monitoring of Laboratories During Methotrexate Therapy

Arthritis Care &Research, EarlyView.
Objective To evaluate whether extending the American College of Rheumatology–recommended monitoring interval for complete blood count and liver function tests in patients receiving methotrexate (MTX) affects timely detection of medication‐related toxicity.
Spencer Simko, Ray Zhang, Sohini Mukherjee, Puneet Bajaj, Bonnie L. Bermas   +4 more
wiley   +1 more source

Sequential anaphylaxis and delayed rituximab-induced serum sickness with skin testing findings: a case report

Allergy, Asthma & Clinical Immunology
Background Rituximab can cause immediate and delayed immune reactions, including rituximab-induced serum sickness (RISS). However, the temporal and mechanistic relationship between these reactions is unclear.
Shiori Mori, Utako Okata-Karigane, Masaki Arai, Chiaki Takahashi, Umi Tahara, Ayano Fukushima-Nomura, Eri Matsuki, Katsunori Masaki, Takeya Adachi   +8 more
doaj   +1 more source

Real-world outcomes with rituximab vs. conventional therapy in pemphigus vulgaris: a single-center Romanian cohort

Frontiers in Medicine
BackgroundPemphigus vulgaris (PV) is a rare but potentially life-threatening autoimmune blistering disease. Rituximab has recently gained prominence as a first-line treatment for moderate-to-severe PV, yet real-world evidence from Eastern Europe remains ...
Daciana Elena Brănișteanu, Torello Lotti, Cristina Colac Boțoc, Antonia Elena Huțanu, Cătălina Anca Munteanu, Roxana Paraschiva Ciobanu, Daniel Constantin Brănișteanu, Alin Gabriel Colac, Cătălina Ioana Onu Brănișteanu, George Brănișteanu, Ștefan Vasile Toader, Mihaela Paula Toader   +11 more
doaj   +1 more source